Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

BACKGROUND: Nilotinib (Tasigna®) is a second-generation tyrosine kinase inhibitor that shows faster and deeper molecular responses (MR) in comparison to Imatinib as initial therapy in chronic phase chronic myeloid leukemia (CML). Efficacy and safety data for nilotinib in the Asian population is scar...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Manag Res
Main Authors: Zaidi, Uzma, Kaleem, Bushra, Borhany, Munira, Maqsood, Sidra, Fatima, Naveena, Sufaida, Gul, Ansari, Saqib Hussain, Farzana, Tasneem, Shamsi, Tahir Sultan
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2019
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6388993/
https://ncbi.nlm.nih.gov/pubmed/30863159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S181911
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker